Top Clinical Trials companies in India by Debt to Equity Ratio
India
# |
Name |
Debt to Equity Ratio |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
4.17
|
March 31, 2024 | USD 2.48 | -5.72% |
|
India |
|
| 2 |
2.05
|
March 31, 2024 | USD 1.17 | -2.96% |
|
India |
|
| 3 |
1.28
|
March 31, 2024 | USD 0.53 | -2.29% |
|
India |
|
| 4 |
1.20
|
March 31, 2024 | USD 6.81 | -4.55% |
|
India |
|
| 5 |
1.18
|
March 31, 2024 | USD 7.96 | -5.16% |
|
India |
|
| 6 |
1.08
|
March 31, 2024 | USD 6.00 | -1.32% |
|
India |
|
| 7 |
1.08
|
March 31, 2024 | USD 15.36 | -4.42% |
|
India |
|
| 8 |
0.86
|
March 31, 2024 | USD 1.51 | -1.73% |
|
India |
|
| 9 |
0.82
|
March 31, 2024 | USD 4.17 | -3.26% |
|
India |
|
| 10 |
0.79
|
March 31, 2024 | USD 1.31 | 0.60% |
|
India |
|
| 11 |
0.74
|
March 31, 2024 | USD 1.75 | -2.24% |
|
India |
|
| 12 |
0.70
|
March 31, 2024 | USD 16.63 | -4.25% |
|
India |
|
| 13 |
0.67
|
March 31, 2024 | USD 11.46 | 0.36% |
|
India |
|
| 14 |
0.63
|
March 31, 2024 | USD 7.01 | -2.13% |
|
India |
|
| 15 |
0.63
|
March 31, 2024 | USD 4.54 | -3.97% |
|
India |
|
| 16 |
0.59
|
March 31, 2024 | USD 0.37 | -8.26% |
|
India |
|
| 17 |
0.59
|
March 31, 2024 | USD 35.78 | -1.94% |
|
India |
|
| 18 |
0.57
|
March 31, 2024 | USD 13.68 | -3.82% |
|
India |
|
| 19 |
0.52
|
March 31, 2024 | USD 2.30 | -4.45% |
|
India |
|
| 20 |
0.49
|
March 31, 2024 | USD 1.73 | -3.30% |
|
India |
|
| 21 |
0.47
|
March 31, 2024 | USD 1.14 | -4.23% |
|
India |
|
| 22 |
0.44
|
March 31, 2024 | USD 4.54 | -1.98% |
|
India |
|
| 23 |
0.41
|
March 31, 2024 | USD 6.36 | -2.20% |
|
India |
|
| 24 |
0.34
|
March 31, 2024 | USD 6.80 | -3.84% |
|
India |
|
| 25 |
0.32
|
March 31, 2024 | USD 1.13 | -4.28% |
|
India |
|
| 26 |
0.30
|
March 31, 2024 | USD 2.87 | -3.41% |
|
India |
|
| 27 |
0.30
|
March 31, 2024 | USD 0.90 | 0.45% |
|
India |
|
| 28 |
0.29
|
March 31, 2024 | USD 9.81 | -4.71% |
|
India |
|
| 29 |
0.29
|
March 31, 2024 | USD 0.18 | -1.69% |
|
India |
|
| 30 |
0.25
|
March 31, 2024 | USD 2.42 | -3.82% |
|
India |
|
| 31 |
0.25
|
March 31, 2024 | USD 0.21 | 2.13% |
|
India |
|
| 32 |
0.23
|
March 31, 2024 | USD 16.36 | -1.17% |
|
India |
|
| 33 |
0.22
|
March 31, 2024 | USD 13.22 | -1.73% |
|
India |
|
| 34 |
0.20
|
March 31, 2024 | USD 23.82 | -3.94% |
|
India |
|
| 35 |
0.20
|
March 31, 2024 | USD 1.96 | -3.91% |
|
India |
|
| 36 |
0.18
|
March 31, 2024 | USD 20.54 | -0.02% |
|
India |
|
| 37 |
0.18
|
March 31, 2024 | USD 3.70 | 0.83% |
|
India |
|
| 38 |
0.16
|
March 31, 2024 | USD 16.74 | -3.08% |
|
India |
|
| 39 |
0.15
|
March 31, 2024 | USD 0.81 | 2.26% |
|
India |
|
| 40 |
0.13
|
March 31, 2024 | USD 8.32 | -1.15% |
|
India |
|
| 41 |
0.13
|
March 31, 2024 | USD 14.60 | -15.38% |
|
India |
|
| 42 |
0.13
|
March 31, 2024 | USD 18.58 | -3.14% |
|
India |
|
| 43 |
0.12
|
March 31, 2024 | USD 2.90 | -5.10% |
|
India |
|
| 44 |
0.12
|
March 31, 2024 | USD 14.32 | -3.90% |
|
India |
|
| 45 |
0.11
|
March 31, 2024 | USD 10.00 | -1.50% |
|
India |
|
| 46 |
0.10
|
March 31, 2024 | USD 1.65 | -3.32% |
|
India |
|
| 47 |
0.08
|
March 31, 2024 | USD 3.61 | -11.36% |
|
India |
|
| 48 |
0.08
|
March 31, 2024 | USD 8.63 | -2.94% |
|
India |
|
| 49 |
0.07
|
March 31, 2024 | USD 157.44 | -6.12% |
|
India |
|
| 50 |
0.07
|
March 31, 2024 | USD 13.94 | -0.13% |
|
India |
Frequently Asked Questions
-
Which Clinical Trials company in India has the highest Debt to Equity Ratio ?
The Clinical Trials company in India with the highest Debt to Equity Ratio is Wanbury Limited (NSE: WANBURY.NS) at 4.17.
-
Which Clinical Trials company in India has the lowest Debt to Equity Ratio ?
The Clinical Trials company in India with the lowest Debt to Equity Ratio is TAKE Solutions Limited (NSE: TAKE.NS) at -4.18.
-
What are the top 10 Clinical Trials companies in India by Debt to Equity Ratio ?
The top 10 Clinical Trials companies in India by Debt to Equity Ratio are Wanbury Limited, Bal Pharma Limited, Vineet Laboratories Limited, Bajaj HealthCare Limited, Strides Pharma Science Limited, Solara Active Pharma Sciences Limited, Eris Lifesciences Limited, Lyka Labs Limited, Biocon Limited and Mangalam Drugs & Organics Limited.
-
What are the bottom 10 Clinical Trials companies in India by Debt to Equity Ratio ?
The bottom 10 Clinical Trials companies in India by Debt to Equity Ratio are TAKE Solutions Limited, Krebs Biochemicals & Industries Limited, Ind-Swift Limited, Suven Life Sciences Limited, Concord Biotech Limited, AstraZeneca Pharma India Limited, Supriya Lifescience Limited, FDC Limited, GlaxoSmithKline Pharmaceuticals Limited and Ind-Swift Laboratories Limited.
